
QIAGEN N.V. QGEN
Annual report 2025
added 04-18-2026
QIAGEN N.V. Total Inventories 2011-2026 | QGEN
Annual Total Inventories QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 302 M | 279 M | 398 M | 358 M | 328 M | 291 M | 171 M | 163 M | 156 M | 137 M | 137 M | 132 M | 128 M | 135 M | 132 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 398 M | 128 M | 216 M |
Quarterly Total Inventories QIAGEN N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 328 M | - | - | - | 291 M | - | - | - | 171 M | - | - | - | 163 M | - | - | - | 156 M | - | - | - | 137 M | - | - | - | 137 M | - | - | - | 132 M | - | - | - | 128 M | - | - | - | 135 M | - | - | - | 132 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 328 M | 128 M | 174 M |
Total Inventories of other stocks in the Diagnostics research industry
| Issuer | Total Inventories | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
6.83 M | - | -8.98 % | $ 14.8 K | ||
|
Heska Corporation
HSKA
|
60 M | - | - | $ 1.31 B | ||
|
Quest Diagnostics Incorporated
DGX
|
189 M | $ 205.06 | 0.27 % | $ 22.8 B | ||
|
Co-Diagnostics
CODX
|
992 K | $ 4.22 | -6.22 % | $ 5.61 M | ||
|
Castle Biosciences
CSTL
|
10.3 M | $ 21.08 | - | $ 611 M | ||
|
Aspira Women's Health
AWH
|
256 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.85 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
757 K | - | -13.05 % | $ 7.29 M | ||
|
ICON Public Limited Company
ICLR
|
2.3 M | $ 149.4 | -1.59 % | $ 11.7 B | ||
|
Guardant Health
GH
|
85.9 M | $ 130.85 | 0.56 % | $ 16.4 B | ||
|
Illumina
ILMN
|
564 M | $ 164.29 | 2.66 % | $ 25.5 B | ||
|
CareDx, Inc
CDNA
|
26.7 M | $ 23.06 | 1.36 % | $ 1.23 B | ||
|
Chembio Diagnostics
CEMI
|
7.72 M | - | 0.22 % | $ 16.8 M | ||
|
Interpace Biosciences
IDXG
|
1.11 M | $ 1.79 | 2.87 % | $ 7.92 M | ||
|
HTG Molecular Diagnostics
HTGM
|
909 K | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
45.9 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
1 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
64.7 M | $ 101.94 | 1.96 % | $ 6.88 B | ||
|
Charles River Laboratories International
CRL
|
299 M | $ 189.61 | -0.2 % | $ 9.4 B | ||
|
Pacific Biosciences of California
PACB
|
49.3 M | $ 1.38 | 0.36 % | $ 414 M | ||
|
Exact Sciences Corporation
EXAS
|
166 M | - | - | $ 19.8 B | ||
|
Mettler-Toledo International
MTD
|
387 M | $ 1 135.13 | -2.39 % | $ 23.4 B | ||
|
NeoGenomics
NEO
|
28.6 M | $ 11.71 | 2.32 % | $ 1.5 B | ||
|
Myriad Genetics
MYGN
|
30.6 M | $ 4.63 | 1.98 % | $ 429 M | ||
|
Natera
NTRA
|
68.4 M | $ 216.72 | -2.74 % | $ 29.6 B | ||
|
Senseonics Holdings
SENS
|
6.7 M | $ 7.23 | -2.69 % | $ 302 M | ||
|
Soleno Therapeutics
SLNO
|
15 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
1.49 M | $ 2.04 | -0.54 % | $ 4.69 M | ||
|
Laboratory Corporation of America Holdings
LH
|
535 M | $ 272.38 | 0.44 % | $ 22.7 B | ||
|
Twist Bioscience Corporation
TWST
|
28.3 M | $ 68.29 | -2.53 % | $ 4.08 B | ||
|
Thermo Fisher Scientific
TMO
|
5.42 B | $ 486.89 | -1.51 % | $ 184 B | ||
|
Motus GI Holdings
MOTS
|
496 K | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
191 M | $ 9.23 | -0.65 % | $ 2 B | ||
|
Invitae Corporation
NVTA
|
30.4 M | - | - | $ 21.2 M |